These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 22801274)

  • 1. [Ion channel therapy of ischemic heart disease].
    Conti CR
    Zhonghua Xin Xue Guan Bing Za Zhi; 2012 Mar; 40(3):254-5. PubMed ID: 22801274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ion channel therapy of ischemic heart disease: from calcium channel blockers to late sodium current inhibition.
    Conti CR
    Clin Cardiol; 2011 Feb; 34(2):66-7. PubMed ID: 21298648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electrophysiological effects of protopine in cardiac myocytes: inhibition of multiple cation channel currents.
    Song LS; Ren GJ; Chen ZL; Chen ZH; Zhou ZN; Cheng H
    Br J Pharmacol; 2000 Mar; 129(5):893-900. PubMed ID: 10696087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The mitochondrial permeability transition pore and the Ca2+-activated K+ channel contribute to the cardioprotection conferred by tumor necrosis factor-alpha.
    Gao Q; Zhang SZ; Cao CM; Bruce IC; Xia Q
    Cytokine; 2005 Dec; 32(5):199-205. PubMed ID: 16260145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myocardial metabolism: pharmacological manipulation in myocardial ischaemia.
    Mitra B; Panja M
    J Assoc Physicians India; 2005 Jun; 53():552-60. PubMed ID: 16121812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Membrane ion channels and cardiovascular ATP-sensitive K+ channels.
    Cavero I; Guillon JM
    Cardiologia; 1993 Dec; 38(12 Suppl 1):445-52. PubMed ID: 7517343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The effect of antianginal preparations on the hemodynamics and metabolism of the ischemic myocardium].
    Makolkin VI; Vakhliaev VD
    Eksp Klin Farmakol; 1996; 59(4):18-20. PubMed ID: 9026181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ATP-Sensitive potassium channels: a review of their cardioprotective pharmacology.
    Grover GJ; Garlid KD
    J Mol Cell Cardiol; 2000 Apr; 32(4):677-95. PubMed ID: 10756123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Calcium antagonists and ischemic heart disease].
    Simon K; Vályi P; Szépvölgyi A; Badics A; Böhm T
    Orv Hetil; 1996 Sep; 137(39):2131-6. PubMed ID: 8927361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drugs acting on the heart in therapy of silent myocardial ischemia].
    Motz W; Scheler S; Strauer BE
    Internist (Berl); 1992 Oct; 33(10):695-700. PubMed ID: 1358855
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of metabolic modulators in ischemic heart disease: an overview.
    Kalra BS; Roy V
    J Clin Pharmacol; 2012 Mar; 52(3):292-305. PubMed ID: 21383339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetes and ATP-sensitive potassium channel openers and blockers in isolated ischemic/reperfused hearts.
    Tosaki A; Engelman DT; Engelman RM; Das DK
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1115-23. PubMed ID: 8531071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prevention and therapy of perioperative myocardial ischemia].
    Bardenheuer HJ; Martin E
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1995 May; 30(3):133-5. PubMed ID: 7605831
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacotherapy of ischemic heart disease.
    Clem JR
    AACN Clin Issues; 1995 Aug; 6(3):404-17; quiz 493-4. PubMed ID: 7627785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A possible involvement of sodium channel blockade of class-I-type antiarrhythmic agents in postischemic contractile recovery of isolated, perfused hearts.
    Takeo S; Tanonaka K; Hayashi M; Yamamoto K; Liu JX; Kamiyama T; Yamaguchi N; Miura A; Natsukawa T
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1403-9. PubMed ID: 7791114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of K(atp)channel activation on myocardial cationic and energetic status during ischemia and reperfusion: role in cardioprotection.
    Fukuda H; Luo CS; Gu X; Guo L; Digerness SB; Li J; Pike MM
    J Mol Cell Cardiol; 2001 Mar; 33(3):545-60. PubMed ID: 11181022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trimetazidine and the contractile response of dysfunctional myocardium in ischaemic cardiomyopathy.
    Belardinelli R
    Rev Port Cardiol; 2000 Nov; 19 Suppl 5():V35-9. PubMed ID: 11206102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heart rate in ischemic heart disease. The innovation of ivabradine: more than pure heart rate reduction.
    Rosano GM; Vitale C; Volterrani M
    Adv Ther; 2010 Apr; 27(4):202-10. PubMed ID: 20495895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cardiac sarcolemmal ATP-sensitive potassium channel as a novel target for anti-arrhythmic therapy.
    Billman GE
    Pharmacol Ther; 2008 Oct; 120(1):54-70. PubMed ID: 18708091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Ion channels and arrhythmias].
    Borchard U; Hafner D
    Z Kardiol; 2000; 89 Suppl 3():6-12. PubMed ID: 10810780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.